vs
EXACT SCIENCES CORP（EXAS）与STARWOOD PROPERTY TRUST, INC.（STWD）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是STARWOOD PROPERTY TRUST, INC.的1.8倍（$878.4M vs $492.9M），STARWOOD PROPERTY TRUST, INC.净利率更高（19.7% vs -9.8%，领先29.4%），EXACT SCIENCES CORP同比增速更快（23.1% vs 8.5%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -2.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
喜达屋酒店及度假村国际集团是全球规模最大的酒店企业之一，业务涵盖酒店、度假村、水疗中心、住宅及度假产权物业的持有、运营、特许经营与管理。集团前身为1969年成立的房地产投资信托基金，1995年完成收购重组，旗下共11个品牌，管理及特许经营的物业共计1297处。
EXAS vs STWD — 直观对比
营收规模更大
EXAS
是对方的1.8倍
$492.9M
营收增速更快
EXAS
高出14.6%
8.5%
净利率更高
STWD
高出29.4%
-9.8%
两年增速更快
EXAS
近两年复合增速
-2.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $492.9M |
| 净利润 | $-86.0M | $96.9M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 26.6% |
| 净利率 | -9.8% | 19.7% |
| 营收同比 | 23.1% | 8.5% |
| 净利润同比 | 90.1% | 87.7% |
| 每股收益（稀释后） | $-0.45 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSTWD
| Q4 25 | $878.4M | $492.9M | ||
| Q3 25 | $850.7M | $488.9M | ||
| Q2 25 | $811.1M | $444.3M | ||
| Q1 25 | $706.8M | $418.2M | ||
| Q4 24 | $713.4M | $454.4M | ||
| Q3 24 | $708.7M | $479.5M | ||
| Q2 24 | $699.3M | $489.8M | ||
| Q1 24 | $637.5M | $523.1M |
净利润EXASSTWD
| Q4 25 | $-86.0M | $96.9M | ||
| Q3 25 | $-19.6M | $72.6M | ||
| Q2 25 | $-1.2M | $129.8M | ||
| Q1 25 | $-101.2M | $112.3M | ||
| Q4 24 | $-864.6M | $51.6M | ||
| Q3 24 | $-38.2M | $76.1M | ||
| Q2 24 | $-15.8M | $77.9M | ||
| Q1 24 | $-110.2M | $154.3M |
毛利率EXASSTWD
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASSTWD
| Q4 25 | -9.4% | 26.6% | ||
| Q3 25 | -3.0% | 19.1% | ||
| Q2 25 | -0.3% | 30.5% | ||
| Q1 25 | -13.6% | 28.7% | ||
| Q4 24 | -122.8% | 15.1% | ||
| Q3 24 | -5.6% | 17.2% | ||
| Q2 24 | -3.8% | 19.1% | ||
| Q1 24 | -16.7% | 30.8% |
净利率EXASSTWD
| Q4 25 | -9.8% | 19.7% | ||
| Q3 25 | -2.3% | 14.8% | ||
| Q2 25 | -0.1% | 29.2% | ||
| Q1 25 | -14.3% | 26.8% | ||
| Q4 24 | -121.2% | 11.4% | ||
| Q3 24 | -5.4% | 15.9% | ||
| Q2 24 | -2.3% | 15.9% | ||
| Q1 24 | -17.3% | 29.5% |
每股收益（稀释后）EXASSTWD
| Q4 25 | $-0.45 | $0.25 | ||
| Q3 25 | $-0.10 | $0.19 | ||
| Q2 25 | $-0.01 | $0.38 | ||
| Q1 25 | $-0.54 | $0.33 | ||
| Q4 24 | $-4.69 | $0.15 | ||
| Q3 24 | $-0.21 | $0.23 | ||
| Q2 24 | $-0.09 | $0.24 | ||
| Q1 24 | $-0.60 | $0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $499.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $6.8B |
| 总资产 | $5.9B | $63.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASSTWD
| Q4 25 | $964.7M | $499.5M | ||
| Q3 25 | $1.0B | $301.1M | ||
| Q2 25 | $858.4M | $259.9M | ||
| Q1 25 | $786.2M | $440.6M | ||
| Q4 24 | $1.0B | $377.8M | ||
| Q3 24 | $1.0B | $357.9M | ||
| Q2 24 | $946.8M | $259.3M | ||
| Q1 24 | $652.1M | $327.4M |
股东权益EXASSTWD
| Q4 25 | $2.4B | $6.8B | ||
| Q3 25 | $2.5B | $6.9B | ||
| Q2 25 | $2.5B | $6.4B | ||
| Q1 25 | $2.4B | $6.4B | ||
| Q4 24 | $2.4B | $6.4B | ||
| Q3 24 | $3.2B | $6.5B | ||
| Q2 24 | $3.2B | $6.2B | ||
| Q1 24 | $3.1B | $6.3B |
总资产EXASSTWD
| Q4 25 | $5.9B | $63.2B | ||
| Q3 25 | $5.9B | $62.4B | ||
| Q2 25 | $5.8B | $62.4B | ||
| Q1 25 | $5.7B | $62.2B | ||
| Q4 24 | $5.9B | $62.6B | ||
| Q3 24 | $6.7B | $64.2B | ||
| Q2 24 | $6.7B | $64.1B | ||
| Q1 24 | $6.4B | $66.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $488.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 5.04× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASSTWD
| Q4 25 | $151.7M | $488.8M | ||
| Q3 25 | $219.9M | $337.6M | ||
| Q2 25 | $89.0M | $-87.4M | ||
| Q1 25 | $30.8M | $238.9M | ||
| Q4 24 | $47.1M | $295.6M | ||
| Q3 24 | $138.7M | $241.8M | ||
| Q2 24 | $107.1M | $53.3M | ||
| Q1 24 | $-82.3M | $55.9M |
自由现金流EXASSTWD
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASSTWD
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASSTWD
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASSTWD
| Q4 25 | — | 5.04× | ||
| Q3 25 | — | 4.65× | ||
| Q2 25 | — | -0.67× | ||
| Q1 25 | — | 2.13× | ||
| Q4 24 | — | 5.72× | ||
| Q3 24 | — | 3.18× | ||
| Q2 24 | — | 0.68× | ||
| Q1 24 | — | 0.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
STWD
| Commercial And Residential Lending Segment | $335.2M | 68% |
| Infrastructure Lending Segment | $70.3M | 14% |
| Property Segment | $57.8M | 12% |
| Other | $29.7M | 6% |
